Published Date : Mar 29, 2017
ALBANY, New York, March 29, 2017 – MarketResearchReports.biz has announced the addition of a new report to its repository, titled “Frontier Pharma: Melanoma Therapeutics - Cytokine and Multiple Targeted Small Molecules and MAbs Dominate Pipeline and First-In-Class Innovation.” The report targets audiences such as pharmaceutical companies, research institutes, hospitals, and healthcare organizations, presenting them the latest technological advancements in melanoma therapeutics. The report provides insights into the current commercial and clinical landscape by considering disease pathogenesis, prognosis, diagnosis, and available treatment strategies.
The report observes that there are three types of skin cancer: melanoma, basal cell carcinoma, and squamous cell carcinoma. Out of these, melanoma is the most serious skin cancer, formed from pigment-containing cells in the skin. Although exposure to UV radiation is the most common cause of melanoma, genes can also cause this condition, for which treatments such as radiation therapy, surgery, and pharmacotherapy are available. Improving healthcare infrastructure across several emerging economies and technological advancements in the field are the factors driving the demand for melanoma therapeutics. According to the 81-page report, vast unmet needs remains despite significant advances in therapy options.
Approval and uptake of premium priced products, effective immunotherapies, and government initiatives in developed as well as emerging economies are some of the other factors augmenting the demand in the melanoma therapeutics market. However, factors such as lack of awareness in some developing regions, economic crisis, high cost associated with the therapy, and regulatory issues are challenging the market for melanoma therapeutics.
For Sample Copy, click here: http://www.marketresearchreports.biz/sample/sample/950607
In the section on the case for innovation in the melanoma therapeutics market, the report studies the growing number of opportunities for biologic products, diversification of molecular targets, innovative first-in-class product developments, regulatory and reimbursement policy shifts, and sustained innovation.
By disease, melanoma can be of several types including ocular, mucosal melanoma, cutaneous, melanoma of the internal organs and soft tissues, and advanced melanoma. The report throws light on the etiology of melanoma, including phenotypic characteristics, exposure to ultraviolet radiation, inherited genetic factors, non-inherited genetic factors, xeroderma pigmentosum, and Parkinson’s disease. The report assesses the pipeline product innovations by molecule type, stage of development and molecular target, comparative distribution of programs between the melanoma therapeutics market and pipeline by molecular target, and first-in-class pipeline programs focusing on novel molecular targets. The chapter on signaling network and innovation alignment explores the complexity of signaling networks, signaling pathways, disease causing mutations, and first-in-class matrix assessment.
To understand the lucrativeness of the melanoma therapeutics market and its changing competitive dynamics, the report has a dedicated chapter on deals and strategic consolidations, covering industry-wide first-in-class deals, melanoma deals landscape, licensing deals, deals by region, value, development stage, and molecule type. The report also includes first-in-class programs that are not involved in licensing and co-development deals.
The report answers some essential questions, such as which pipeline molecule targets and molecular types are most prominent and augur well for the future of melanoma therapeutics market, which are the most promising first-in-class targets, what is the proportion of first-in-class targets to first-in-class products at different development stages, and which molecule types dominate the deals landscape.
To order report Call Toll Free: 866-997-4948 or send an email on email@example.com